Molecular therapy for Pulmonary Hypertension (PAH): Resistin inhibits pulmonary hypertension via induction of PDLIM5, 8/February/2015, 14.25

Molecular therapy for Pulmonary Hypertension (PAH): Resistin inhibits pulmonary hypertension via induction of PDLIM5, 8/February/2015, 14.25

Molecular therapy for Pulmonary Hypertension (PAH): Resistin inhibits pulmonary hypertension via induction of PDLIM5, 8/February/2015, 14.25 150 150

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Significance: This study suggests, for the first time, that Resistin, by suppressing the expression of its target gene, it may increase the expression of PDLIM5. Thereby, it may inhibit pulmonary hypertension. Together, pharmacological formulations encompassing “Resistin or its activators may be used to treat pulmonary arterial hypertension (PAH).

Amount: $ 300*

Undisclosed information: How Resistin  increases the expression of PDLIM5

To citeBoominathan, Molecular therapy for Pulmonary Hypertension (PAH): Resistin inhibits pulmonary hypertension via induction of PDLIM5, 8/February/2015,  14.25,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org